BIOGRAPHICAL SKETCH 　 　

NAME:   Zhou , Yunfeng 　 　

POSITION TITLE: Assistant   Professor of Physiology ; Shenzhen University School of Medicine 　 　

EDUCATION/TRAINING   　 　

A.  Personal Statement 　 　

My long-standing research interests lie in the r ole of n uclear r eceptors and m etabolites of arachidonic acid in the p athogenesis of d iabetes, f atty liver and chronic k idney diseases . My research has been continuously supported by the National Natural Science Foundation in China (NSFC), the Natural Science Foundation  in Guangdong Province and Shenzhen Basic Research Fund . I have published > 2 0 papers in the peer-reviewed professional journals. 　 　

B.  Positions and Honors 　 　

Positions and Employment 　 　

02/2011–10/2013 Assistant  Professor of Physiology, School of Medicine, Peking University , Beijing, China 　 　

10/2013 – present Assistant  Professor of Physiology, School of Medicine, Shenzhen University , Shenzhen , China 　 　

Attending International Meetings 　 　

1.  Oral Presentation, Annual Meeting of American Society of Nephrology, Oct 27-Nov 1, 2009, San Diego, USA 　 　

2.  Poster   Presentation, 2012 I nternational A cademic C onference of P hysiological S cience , Nov 1 -4 , 20 12 , S uzhou , China 　 　

3.  Oral Presentation, European Medical and Clinical Congress (EMCC 2017 ) , Aug  2 2 - 24 , 20 17 , Stockholm, Sweden 　 　

Other Experience and Honors 　 　

1.  Best Poster Paper Award, the 9th Conference of Chinese Association of Pathophysiology , 2010 　 　

2.  S econd Prize  Presentation , Annual Meeting of the Chinese Physiological Society , 2011 　 　

3.  Best Poster Paper Award, I nternational A cademic C onference of P hysiological S cience , 2012 　 　

4.  Second Prize   Presentation , Annual Meeting of the Chinese Physiological Society , 2013 　 　

5.  Best Poster Paper Award, the Conference of Chinese Association of Pathophysiology , 2014 　 　

C.  Contributions to Science  (*: corresponding/co-corresponding author) 　 　

A full list of my publications (in a total of 21 ) is enclosed at the end of this document. 　 　

1.  Role of SREBP-1 and PPAR α   in the mechanism of hyperlipidemia  and  proteinuria   in nephrotic syndrome 　 　

My Ph.D research at the Peking Unversity Diabetes Center focused on elucidating the underlying mechanisms by which nephrotic syndrome (NS) induces hyperlipidemia and proteinuria. We found that over-activation of the SREBP-1 pathway may represent a possible underlying mechanism for the hyperlipidemia in nephrotic syndrome (Am J Physiol Renal Physiol ,  2008). I also revealed that deficiency of a member of nuclear receptor superfamily, peroxisome proliferator-activated receptor-α (PPARα), may exacerbate doxorubicin-related renal injury, at least in part, due to increased podocyte apoptosis.  Finally, we found that PPARα activation may protect podocytes from injury in an in vitro  model of podocyte injury ( Kidney Int ,  2011 ). 　 　

1)  Zhou Y #, Kong X#, Zhao P, Yang H, Chen L, Miao J, Zhang X, Yang J, Ding J, Guan Y*. Peroxisome proliferator-activated receptor- α  is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011 79(12):1302-1311. 　 　

2)  Zhou Y , Zhang X, Chen L, Wu J, Dang H, Wei MF, Fan Y, Zhang Y, Zhu Y, Wang N, Breyer MD, Guan Y*. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008 295(3): F662-F671. 　 　

2.  Role of CYP4A14  in the mechanism of fatty liver and chronic kidney diseases 　 　

Following my Ph.D.  I started to investigate the roles of cytochrome P450 4A14 (CYP4A14), the target gene of PPAR α , in non-alcoholic fatty liver and chronic kidney diseases, such as diabetic nephropathy and angiotensin II-induced renal damage. We found  that hepatic CYP4A14 levels were upregulated in three animal models of hepatic steatosis, including high-fat diet, methionine-choline-deficient (MCD) diet - induced steatohepatitis and db/db mice. Over - expression of CYP4A14 in the livers of C57BL/6 mice promoted the occurrence  of a fatty liver and CYP4A14 gene deficiency in mice attenuate d  hepatic fibrosis and  steatohepatitis. Thus, CYP4A14 may represent a potential therapeutic target for the treatment of non-alcoholic fatty liver diseases   (Proc Natl Acad Sci U S A, 2017). We also  found  that attenuated renal fibrosis in AngII-treated CYP4A14 ^-/-  mice may result from both reduced systemic blood pressure and renal 20-HETE (the primary eicosanoid catabolized by CYP4A14) production. CYP4A14 may represent a useful target for the treatment of AngII-associated renal damage  (BBA-Molecular Basis of Disease, 2018). 　 　

1)  Yunfeng Zhou , Jingwei Yu , Jia Liu , Rong Cao , Wen Su , Sha Li , Shiqi Ye , Chenggang Zhu , Xiaolin Zhang , Hu Xu , Hua Chen , Xiaoyan Zhang * , YoufeiGuan * . I nduction of cytochrome P450 4A14   contributes to angiotensin II-induced renal   fibrosis in mice, BBA - Molecular Basis of Disease, 2018.Mar, 1864(3): 860 - 870 . 　 　

2)  Zhang X#, Li S#,  Zhou Y #, Su W, Ruan X, Wang B, Zheng F, Warner M, Gustafsson JA*, Guan Y*. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc Natl Acad Sci U S A. 2017 114(12):3181-3185.

D.  Research Support 　 　

Ongoing Research Support 　 　

Guangdong Science Foundation  project (2014A020212423 ) 10/01/20 15  to 10/01/20 18 　 　

Yunfeng Zhou, PI                         ￥ 5 0,000 　 　

Role of Arachidonic Acidω-hydroxylase CYP4A14 in the chronic kidney diseases

Shenzhen Science and Technology Innovation Commission grant (JCYJ201708183000804)                          03/31/20 18  to 03/31/20 20 　 　

Yunfeng Zhou, PI                     ￥ 50 0,000 　 　

Role of Arachidonic Acidω-hydroxylase CYP4A14 in hypertentive-related  renal damage

Completed Research Support 　 　

NSFC (China) ( 81100611 ) 01/01/2012 to 12/31/2014 　 　

Yunfeng Zhou, PI ￥ 300,000 　 　

Role of Arachidonic Acidω-hydroxylase CYP4A14 in the Glucose and Lipid Metabolism of Liver

Shenzhen Science and Technology Innovation Commission grant ( JCYJ20150324141711629 )                   01/01/20 16  to 12/31/20 17 　 　

Yunfeng Zhou, PI              ￥ 30 0,000 　 　

Role of Arachidonic Acidω-hydroxylase CYP4A14 in diabetic nephropathy

E.  Peer-reviewed publications (*: corresponding author) 　 　

1.  Yunfeng Zhou , Jingwei Yu, Jia Liu, Rong Cao, Wen Su, Sha Li, Shiqi Ye, Chenggang Zhu, Xiaolin Zhang, Hu Xu, Hua Chen, Xiaoyan Zhang*, YoufeiGuan*. Induction of cytochrome P450 4A14  contributes to angiotensin II-induced renal fibrosis in mice, BBA - Molecular Basis of Disease, 2018.Mar, 1864(3): 860-870. 　 　

2.  Zhang X#, Li S#, Zhou Y #, Su W, Ruan X, Wang B, Zheng F, Warner M, Gustafsson JA*, Guan Y*. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc Natl Acad Sci U S A. 2017 114(12):3181-3185. 　 　

3.  Yalin Jiang#, Yunfeng Zhou #, Yufeng Zheng, Hong Guo, Lei Gao, Pan Chen, Dandan Feng, Ran Qi, Xiaozhen Li, Yongchao Chang, FongFong Chu, Qiang Gao*. Expression of inositol‑requiring enzyme 1β is downregulated in colorectal cancer. Oncol Lett. 2017 13(3):1109-1118. 　 　

4.  Li F, Zhang N, Li Z, Deng L, Zhang J, Zhou Y *. Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice. Exp Ther Med. 2017 13(2):495-502. 　 　

5.  Li H#, Zhou Y #, Zheng Y, Guo H, Gao L, Chen P, Feng D, Wu L, Yang M, Qi Y, Guo H, Chang Y, Chu FF, Gao Q*. The Gastric Mucosa from Patients Infected with CagA+ or VacA+ Helicobacter pylori Has a Lower Level of Dual Oxidase-2 Expression than Uninfected or Infected with CagA-/VacA- H. pylori. Dig Dis Sci. 2016 61(8):2328-2337. 　 　

6.  Qi R#, Zhou Y #, Li X, Guo H, Gao L, Wu L, Wang Y, Gao Q*. DUOX2 Expression Is Increased in Barrett Esophagus and Cancerous Tissues of Stomach and Colon. Gastroenterol Res Pract. 2016 2016:1835684. 　 　

7.  Zhou Y , Zhang X, Guan Y*. Human antigen R: A novel therapeutic target for diabetic nephropathy? J Diabetes. 2015 7(4):462-464. 　 　

8.  Wang C#, Chi Y#, Li J#, Miao Y, Li S, Su W, Jia S, Chen Z, Du S, Zhang X,  Zhou Y , Wu W, Zhu M, Wang Z, Yang H, Xu G, Wang S, Yang J*, Guan Y*. FAM3A activates PI3K p110α/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis. Hepatology. 2014 59(5):1779-1790. 　 　

9.  Zheng S#, Liu J#, Han Q, Huang S, Su W, Fu J, Jia X, Du S, Zhou Y , Zhang X, Guan Y*. Metformin induces renal medullary interstitial cell apoptosis in type 2 diabetic mice. J Diabetes. 2014 6(2):132-146. 　 　

10.  Wu J#, Wang C#, Li S#, Li S, Wang W, Li J, Chi Y, Yang H, Kong X, Zhou Y , Dong C, Wang F, Xu G, Yang J, Gustafsson J�*, Guan Y*. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by Liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice. Hepatology. 2013 58(2):617-628. 　 　

11.  Wang Q#, Pang W#, Cui Z, Shi J, Liu Y, Liu B, Zhou Y , Guan Y, Hammock BD, Wang Y*, Zhu Y*. Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage. Am J Physiol Renal Physiol. 2013 304(2):F168-F176.   　 　

12.  Yang S, Yao B, Zhou Y , Yin H, Zhang MZ, Harris RC*. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol. 2012 302(6):F742-F749. 　 　

13.  Yang J, Zhou Y , Guan Y*. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens. 2012 21(1):97-105. 　 　

14.  周云枫 #，李沙#，苏文，黄世铮，蒲丹，管又飞*. 不同脂肪含量的高脂纯化配方饲料对大、小鼠代谢综合征发生的影响. 基础医学与临床. 2012 32(3): 273-277. 　 　

15.  周云枫 ，付佳霖，管又飞*. 微小RNAs与糖尿病肾病. 生理科学进展. 2012 43(5):351-355. 　 　

16.  Han Q#, Zhang X#, Xue R, Yang H,  Zhou Y , Kong X, Zhao P, Li J, Yang J, Zhu Y, Guan Y*. AMPK potentiates hypertonicity-induced apoptosis by suppressing NFκB/COX-2 in medullary interstitial cells. J Am Soc Nephrol. 2011 22(10):1897-1911.   　 　

17.  Zhou Y #, Kong X#, Zhao P, Yang H, Chen L, Miao J, Zhang X, Yang J, Ding J, Guan Y*. Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011 79(12):1302-1311. 　 　

18.  Zhou Y , Zhang X, Chen L, Wu J, Dang H, Wei MF, Fan Y, Zhang Y, Zhu Y, Wang N, Breyer MD, Guan Y*. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008 295(3): F662-F671. 　 　

19.  Yang J, Chen L, Zhang X, Zhou Y , Zhang D, Huo M, Guan Y*. PPARs and Female Reproduction: Evidence from Genetically Manipulated Mice. PPAR Res. 2008 2008:723243. 　 　

20.  周云枫 ，管又飞*. 肾病综合征高脂血症发病机制研究进展. 生理科学进展. 2008 39(1):67-70. 　 　

21.  Wu Y, Ou-Yang JP*, Wu K, Wang Y, Zhou YF , Wen CY. Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacol Sin. 2005 26(3):345-352.